Company ProMIS Neurosciences, Inc. Toronto S.E.

Equities

PMN

CA74346M4065

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimerâs disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

Number of employees: 7

Managers	Title	Age	Since
Neil Warma CEO	Chief Executive Officer	61	21-05-12
Neil Cashman FOU	Founder	72	04-01-22
Eugene Williams CHM	Chairman	64	15-06-28
Daniel Geffken DFI	Director of Finance/CFO	67	17-03-21
Gavin Malenfant COO	Chief Operating Officer	61	21-10-21
Larry Altstiel CTO	Chief Tech/Sci/R&D Officer	74	22-04-18
Suzanne Messere IRC	Investor Relations Contact	-	-
Dennis Chen PRN	Corporate Officer/Principal	-	-
David Wishart PRN	Corporate Officer/Principal	-	21-05-26
Ernest D. Bush PRN	Corporate Officer/Principal	-	18-04-02

Members of the board	Title	Age	Since
William W. Wyman BRD	Director/Board Member	86	14-03-07
Neil Cashman FOU	Founder	72	04-01-22
Neil Warma CEO	Chief Executive Officer	61	21-05-12
Eugene Williams CHM	Chairman	64	15-06-28
Patrick Kirwin BRD	Director/Board Member	-	15-06-28
Josh Mandel-Brehm BRD	Director/Board Member	41	21-08-31
Maggie Shafmaster BRD	Director/Board Member	65	21-09-21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,961,116	14,344,157 ( 75.65 %)	0	75.65 %

Name	Equities	%	Valuation
Sphera Funds Management Ltd. 9.712 %	1,834,042	9.712 %	4 M $
Sphera Funds Management Ltd. 9.712 %	1,834,042	9.712 %	4 M $
Mike Gordon 6.136 %	1,158,846	6.136 %	2 M $
Ally Bridge Group HK Ltd 5.648 %	1,066,674	5.648 %	2 M $
Crocker Mountain LLC 5.325 %	1,005,726	5.325 %	2 M $
Jeremy Sclar 4.420 %	834,763	4.420 %	2 M $
Affinity Asset Advisors LLC 1.408 %	265,958	1.408 %	507 980 $
Eugene Williams 0.8469 %	159,930	0.8469 %	305 466 $
Neil Cashman 0.6085 %	114,921	0.6085 %	219 499 $
Northeast Financial Consultants, Inc. 0.5295 %	100,000	0.5295 %	191 000 $

Name	Equities	%	Valuation
Mike Gordon 42.86 %	30,000,000	42.86 %	57 M $
Jak II LLC 12.86 %	9,000,000	12.86 %	17 M $
Jeremy Sclar 12.86 %	9,000,000	12.86 %	17 M $
KPC Venture Capital LLC 12.86 %	9,000,000	12.86 %	17 M $

Name	Equities	%	Valuation
Mike Gordon 100.00 %	500,000	100.00 %	955 000 $
Jeremy Sclar 60.00 %	300,000	60.00 %	573 000 $

ProMIS Neurosciences, Inc.

1920 Yonge Street Suite 200

M4S 3E2, Toronto

+416 847 6898

http://www.promisneurosciences.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-1.16%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-8.12%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs